Message from the CEO
In over a decade, Samsung Biologics has rapidly evolved into the world’s largest and best-in-class CDMO service partner. We continue to expand our business scope to make the next leap in biopharma, and build greater capabilities to meet new market demand as a top service innovator in the biopharmaceutical industry, while ensuring quality and a stable supply of life-saving drugs.
Since its launch, Samsung Biologics has not only expanded its manufacturing capacity, but also established a solid track record of successful regulatory approvals and award-winning client satisfaction. In an effort to provide the highest level of customer-centric services, Samsung Biologics implemented innovative technologies and processes to provide speed, price competitiveness, quality, and efficiency.
We are facing a time of significant challenges and market dynamics. To respond to the surging demand for biologics, we completed the world's largest biomanufacturing plant, Plant 4, and announced an accelerated construction timeline for our fifth plant, which is expected to be operational by April 2025 as the first facility of our second Bio Campus. Samsung Biologics also has established sales offices in New Jersey, Boston, and San Francisco to work in closer proximity with our clients based in the U.S. and Europe. We will continue to expand the synergies between the new global locations and our main manufacturing sites in Songdo, South Korea.
We embrace responsibility, expertise, and pride in our work, and will continue to improve the accessibility of biomedicines and consequently the quality of life for people around the globe. We will challenge ourselves to improve in all facets of our business through innovation, dedication, and excellence so that we can add meaningful value to all of our clients, partners, and shareholders.
Thank you for your continuous trust and support.